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Abstract
Background: Electromagnetic navigation bronchoscopy (ENB) procedures allow physicians to access peripheral
lung lesions beyond the reach of conventional bronchoscopy. However, published research is primarily limited to
small, single-center studies using previous-generation ENB software. The impact of user experience, patient factors,
and lesion/procedural characteristics remains largely unexplored in a large, multicenter study.
Methods/Design: NAVIGATE (Clinical Evaluation of superDimension™ Navigation System for Electromagnetic
Navigation Bronchoscopy) is a prospective, multicenter, global, cohort study. The study aims to enroll up to 2,500
consecutive subjects presenting for evaluation of lung lesions utilizing the ENB procedure at up to 75 clinical sites
in the United States, Europe, and Asia. Subjects will be assessed at baseline, at the time of procedure, and at 1, 12,
and 24 months post-procedure. The pre-test probability of malignancy will be determined for peripheral lung
nodules. Endpoints include procedure-related adverse events, including pneumothorax, bronchopulmonary
hemorrhage, and respiratory failure, as well as quality of life, and subject satisfaction. Diagnostic yield and accuracy,
repeat biopsy rate, tissue adequacy for genetic testing, and stage at diagnosis will be reported for biopsy
procedures. Complementary technologies, such as fluoroscopy and endobronchial ultrasound, will be explored.
Success rates of fiducial marker placement, dye marking, and lymph node biopsies will be captured when
applicable. Subgroup analyses based on geography, demographics, investigator experience, and lesion and
procedure characteristics are planned.
Discussion: Study enrollment began in April 2015. As of February 19, 2016, 500 subjects had been enrolled at 23
clinical sites with enrollment ongoing. NAVIGATE will be the largest prospective, multicenter clinical study on ENB
procedures to date and will provide real-world experience data on the utility of the ENB procedure in a broad
range of clinical scenarios.
Trial registration: ClinicalTrials.gov NCT02410837. Registered 31 March 2015.
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Background
Lung cancer is the leading cause of cancer death among
both men and women in developed countries globally.
An estimated 1.8 million new cases of lung and airway
cancers occurred worldwide in 2012 [1].
Rapid and precise diagnosis of suspicious lesions is
crucial to determine the optimal treatment for abnor-
malities in the lung found on chest computed tomog-
raphy (CT) imaging. According to the American Cancer
Society’s 2015 estimates, the 5-year survival rate for dis-
tant (metastasized) lung cancer is 4 %, compared to
27 % for regional cancer and 54 % for localized cancer.
However, few lung cancers are diagnosed at an early
stage when more patients are amenable to curative treat-
ment options [2].
The National Lung Screening Trial [3] clearly demon-
strated the efficacy of screening in a defined high-risk
subset of the population. While the results and their
generalizability can be questioned, the trial established
the utility of low-dose CT scanning over conventional
chest radiography. In addition, declining costs of tech-
nology, greater availability of CT imaging, lower radi-
ation dosing, and increased awareness all have led to
more CT scans of the chest. These scans will inevitably
identify abnormalities for which intervention may be
necessary. Current diagnostic options include image-
guided needle biopsy, surgery, and more recently, elec-
tromagnetic navigation bronchoscopy.
ENB is an image-guided approach that uses 3D-
reconstructed CT-scan and sensor location technology
to guide a steerable endoscopic probe to peripheral lung
lesions that may be beyond the reach of conventional
bronchoscopes [4, 5], potentially aiding in diagnosis of
lung cancer at an early stage of disease. This technology
will also allow diagnosis of pulmonary metastases or be-
nign diseases, such as infectious lung lesions or granu-
lomatous disease, without surgical incisions.
Table 1 summarizes 24 original research articles
published to date on the use of ENB procedures to
aid in the diagnosis of peripheral lung lesions [6–29],
most of which have been summarized in several
meta-analyses [30–32]. In the most recent meta-
analysis, the pooled sensitivity, specificity, positive
likelihood ratio, negative likelihood ratio, and diagnos-
tic odds ratio were 82 %, 100 %, 19.36, 0.23, and
97.62, respectively [32]. The pooled pneumothorax
rate was approximately 3 %, of which approximately
1.6 % required chest tube insertion [30].
ENB procedures can also be used to aid in the diagnosis
of mediastinal lymphadenopathy [33], as a localization
tool for dye marking prior to video- or robotic-assisted
thoracoscopic surgery [34], or to place fiducial markers
prior to stereotactic body radiation therapy [35], all in a
single procedure.
Despite these promising results, outcomes following
ENB procedures are widely varied and most evidence to
date is based on single-center analyses. Of the 24 pub-
lished original studies on the use of ENB procedures to
aid in the diagnosis of peripheral lung lesions, only 4
studies were multicenter [9, 10, 19, 29] and only 5 en-
rolled greater than 100 subjects [12, 20, 21, 28, 29] (see
Table 1). The impact of user experience, patient risk fac-
tors, and lesion/procedural characteristics remains
largely unexplored in a large multi-center study. The
lack of clearly defined performance outcomes, varied
definitions of diagnostic yield and accuracy, inconsistent
use of complementary techniques, such as radial endo-
bronchial ultrasound (EBUS), use of older ENB software
versions, and variability in lesions targeted and biopsy
methods also challenge the interpretation of results
across studies. In addition, the full profile of how ENB
procedures are used in daily practice (e.g., peripheral
versus central lesions, lymph node sampling, dye mark-
ing, and fiducial marker placement) is not well under-
stood. As ENB usage increases and is adopted by
community centers with a wide range of user experience
levels, the full safety profile across diverse clinical sce-
narios must be well understood, particularly with respect
to the patient, lesion, and procedural factors associated
with performance outcomes.
NAVIGATE (Clinical Evaluation of superDimension™
Navigation System for Electromagnetic Navigation
Bronchoscopy) aims to enroll up to 2,500 consecutive
subjects at up to 75 sites worldwide. When complete,
NAVIGATE will be the largest prospective, multicen-
ter clinical study of ENB procedures to date. The ob-
jective of this observational study is to evaluate the
safety profile and outcomes following ENB proce-
dures conducted for suspicion of cancer or other dis-
eases in lung lesions, for lymph node biopsy, or for
dye marking or fiducial marker placement. The study
is designed to capture the real-world experience of
ENB use across heterogeneous sites and geographies,
without restriction on ancillary tools or procedures.
The 24-month follow-up will also allow an assess-
ment of long-term diagnostic accuracy and the cor-




This study is being conducted in accordance with the
Declaration of Helsinki and all local regulatory require-
ments. As of February 19, 2016, 23 clinical sites in the
United States and Europe had been activated into study
(see Additional file 1 for the list of activated sites to
date). The protocol was approved by the institutional re-
view board of each participating site. Additional site
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selection is ongoing. Institutional review board approval
will be obtained for each newly activated site prior to
subject enrollment. Inclusion of up to 75 clinical sites is
prespecified per protocol. The study was registered
under ClinicalTrials.gov identifier NCT02410837 on
March 31, 2015, which will be updated as new sites are
activated. All subjects have provided or will provide writ-
ten informed consent prior to enrollment.
Trial design and subject eligibility
NAVIGATE is a prospective, single-arm, multicenter,
post-market, observational study of ENB procedure
use. The study aims to enroll up to 2,500 subjects at up
to 75 clinical sites worldwide, including the United
States, Europe, China, Korea, and Japan. To ensure
heterogeneity of the data, a maximum enrollment per
site will be specified for each region, approximately 75
subjects per site in the US, with other regions to be
determined.
All consecutive patients over the age of 18, who are
candidates for an elective ENB procedure and who
present for evaluation of lung lesions, are eligible for en-
rollment. Exclusion criteria are: (1) the patient is unable
or unwilling to provide informed consent or to comply
with study follow-up schedule; (2) the patient has partic-
ipated in an investigational drug or device research study
within 30 days of enrollment that would interfere with
this study; and (3) the patient is pregnant or nursing.
Table 1 Prior clinical studies on ENB to aid in the diagnosis of peripheral lung lesions
First author and year Study design Number of
centers
Number of subjects Length of
follow-up
Diagnostic yield aided
by ENB procedures (%)
Pneumothorax (%)
Becker 2005 [6] Prospective, single-arm Single-center 29 N.R. 69.0 3.4
Gildea 2006 [7] Prospective, single-arm Single-center 58 Mean
10.5 months
74.1 3.5
Schwarz 2006 [8] Prospective, single-arm Single-center 13 N.R. 69.2 0.0
Eberhardt 2007a [9] Prospective, RCT (EBUS only,
ENB only, or combined)
Multi-center (2) 39 (ENB alone)
40 (ENB + EBUS)
N.R. 59.0 (ENB alone)
87.5 (ENB + EBUS)
5.0
Eberhardt 2007b [10] Prospective, single-arm Multi-center (2) 89 N.R. 67.4 2.2
Makris 2007 [11] Prospective, single-arm Single-center 40 N.R. 62.5 7.5
Wilson 2007 [12] Retrospective, single-arm Single-center 222 6 – 18 months 59.9 1.2
Bertoletti 2009 [13] Prospective, single-arm Single-center 53 >18 months 77.4 4.0
Lamprecht 2009 [14] Retrospective, single-arm Single-center 13 N.R. 76.9 0.0
Eberhardt 2010 [15] Prospective, single-arm Single-center 53 N.R. 75.5 1.9
Seijo 2010 [16] Prospective, single-arm Single-center 51 N.R. 66.7 0.0
Mahajan 2011 [17] Retrospective, single-arm Single-center 48 N.R. 77.0 10.2
Brownback 2012 [18] Retrospective, single-arm Single-center 55 N.R. 74.5 0.0
Jensen 2012 [19] Retrospective, single-arm Multi-center (5) 92 ≥6 months 65.2 3.3
Lamprecht 2012 [20] Prospective, single-arm Single-center 112 N.R. 83.9 1.8
Pearlstein 2012 [21] Retrospective, single-arm Single-center 101 2 years 85.1 5.8
Balbo 2013 [22] Retrospective, single-arm Single-center 40 N.R. 70.7 0.0
Karnak 2013 [23] Prospective, single-arm Single-center 35 ≥2 years 91.4 3.9
Khan 2013 [24] Prospective, single-arm Single-center 24 N.R. 75.0 0.0
Mohanasundaram
2013 [25]
Retrospective, single-arm Single-center 41 ≤2 years 89.4 13.0
Loo 2014 [26] Retrospective, single-arm Single-center 40 N.R. 94.0 0.0
Odronic 2014 [27] Retrospective, single-arm Single-center 91 1 year 85.7 5.3
Bowling 2015 [28] Retrospective, single-arm Single-center 107 ≥18 months 73.6 2.5
Ost 2015 [29] Retrospective Multi-center 39 (ENB a alone)
227 (ENB a + EBUS)
1 year 38.5 (ENB alone)
47.1 (ENB + EBUS)
1.7 %
Acronyms: EBUS endobronchial ultrasound, ENB electromagnetic navigation bronchoscopy, RCT randomized controlled trial
aIncludes 252 cases using the superDimension™ navigation system, 8 cases using other electromagnetic navigation methods, and 14 cases using CT fluoroscopy.
More than one method was used in some patients. In the publication by Ost et al., [29], diagnostic yield included only those cases with a specific malignant or
benign diagnosis. If only inflammatory tissue or lymphocytes was obtained, the procedure was considered nondiagnostic
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Test device
The superDimension™ navigation system, software ver-
sion 6.0 or higher (Medtronic, Minneapolis, MN), will
be used to conduct all ENB procedures [4–6, 8].
Pre-procedure assessments
A full list of subject demographics, lesion characteristics,
and pre-procedure data to be collected is included in
Table 2.
In addition, to assess the value of the ENB procedure
as a decision-making tool, the pre-procedure probability
of malignancy will be assessed for each subject being
evaluated for diagnosis of a pulmonary nodule [36, 37].
Probability will be captured both by the investigator’s
subjective estimation of pretest probability of malig-
nancy and a mathematical model, to allow comparison
between the two methods. The probability model em-
ploys a multiple regression equation including the fol-
lowing factors: (1) subject age; (2) smoking history; (3)
history of extrathoracic malignancy; (4) nodule size; (5)
nodule border characteristics; and (6) nodule location
(see Additional file 2 for the full equation). See Add-
itional file 3 for the definition of peripheral lung lesions.
Procedures
The ENB procedure will be performed per product in-
structions and the institution’s standard practice. All
complementary devices and procedures (e.g., catheter
type, biopsy tools, access tools, fiducial placement or dye
marking, and concomitant imaging, such as radial
EBUS) are at the discretion of the investigator and are
not mandated per the study protocol. All complemen-
tary procedures and devices will be captured (Table 2).
Primary and secondary endpoints
This post-market study is intended to capture clinical
outcomes related to the real-world use of ENB proce-
dures, including but not limited to peripheral lesion bi-
opsies, lymph node biopsies, fiducial marker placement
for radiation therapy, and tumor marking for diagnostic
and therapeutic surgery.
The primary endpoint is the incidence of pneumo-
thorax related to the ENB index procedure rated as
Grade 2 or higher according to the Common Termin-
ology Criteria for Adverse Events (CTCAE) scale
(Table 3) [38]. The primary endpoint was chosen as a
comprehensive endpoint that would be applicable to
all ENB procedures. The secondary endpoints will be
assessed as applicable to the ENB procedure being
conducted.
The following secondary endpoints will evaluated for
all ENB index procedures:
1. Incidence of all pneumothoraces related to ENB
index procedure
2. Incidence of bronchopulmonary hemorrhage related
to ENB index procedure rated as Grade 2 or higher
according to the CTCAE scale
3. Incidence of respiratory failure related to ENB index
procedure rated as Grade 4 or higher according to
the CTCAE scale
4. Subject health status and quality of life evaluated by
EQ-5D-3 L questionnaire (Version 5.1, April 2015)
[39, 40]
5. Subject self-reported satisfaction at 1-month post-
procedure, including referral source, pre-procedure
expectations, pain, willingness to undergo another
ENB procedure, worker productivity, and willingness
to recommend the ENB procedure to family and
friends.
6. ENB procedure effect on subject productivity and
activity using the ENB Productivity and Activity
Questionnaire (ENB-PAQ) at 1-month visit.
The following secondary endpoints will be evaluated
for all ENB index procedures performed for suspicion of





10. Positive predictive value
11. Negative predictive value
12. Repeat biopsy rate due to lack of diagnosis during
ENB index procedure
13. Adequacy of sample for molecular testing and
mutation type (if applicable)
14. Diagnosis
15. Stage at diagnosis (if applicable)
In addition, the following secondary endpoints will be
evaluated for applicable procedures:
7. Success rate of accurate placement of fiducial
markers demonstrated through follow-up imaging
8. Success rate of dye marking demonstrated by
successful surgical resection
9. Success rate of obtaining lymph node biopsy to
provide stage of diagnosis
In addition to the primary and secondary endpoints
listed above, all adverse events related to the ENB
procedure or associated tools will be captured and re-
ported, including all incidences of death, pneumothorax,
bronchopulmonary hemorrhage, and respiratory failure
regardless of CTCAE grade. New scales have also been
developed by the study investigators and validated by ex-
pert consensus (Delphi technique [41]) to provide more
specific criteria for defining the incidence and severity of
bronchopulmonary hemorrhage and pneumothorax in
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subjects undergoing transbronchial lung biopsies under
flexible bronchoscopy. These scales will be evaluated for
the first time in the NAVIGATE study and compared to
the existing CTCAE scale (E. Folch and S. Khandhar, un-
published personal communication; publication in pro-
gress). Additional procedural and follow-up assessments
are listed in Table 2.
Follow-up
Subjects will be evaluated at baseline (within 30 days of
the procedure), on the procedure day, and at 1 month,
12 months, and 24 months post-procedure. Follow-up
will capture any repeat diagnostic procedures or new
diagnoses on any lung nodule evaluated during the ini-
tial ENB index procedure, as well as healthcare
utilization since the ENB index procedure (including
healthcare visits, repeat ENB procedures, transthoracic
biopsy, bronchoscopy, chemotherapy, brachytherapy, ra-
diation therapy, surgical resection, and lymph node dis-
section). All lung nodules evaluated during the initial
ENB index procedure will be followed for confirmation
of ENB-aided diagnoses, including confirmation of ini-
tially negative or inconclusive results.
Investigator training
All investigators must have completed the superDimen-
sion™ navigation system training course prior to enrol-
ling subjects into the study. In order to capture the full
breadth of ENB procedure usage at both high-volume
and low-volume centers, investigators without extensive
experience conducting ENB procedures will be allowed
to perform a maximum of 5 “roll-in cases”.






Subject medical history and baseline status
• Prior invasive lung procedures and surgeries
• Lung function and diffusing capacity
• Antithrombotic medication current and prior status, including
duration of any discontinuation
• Subject risk factors
• Pre-procedure probability of malignancy




• Presence of bronchus sign on computerized tomography (CT)
• Lung zone (peripheral, middle, and proximal thirds)
• Visibility on fluoroscopy (if applicable)
• Positron emission tomography (PET)-positive (yes/no)
• Associated lymphadenopathy
• Distance to closest fissure
• Distance from lesion to pleura
• Preprocedure probability of malignancy (investigator assessment)
Procedural assessments




• Imaging used (fluoroscopy, PET, radial endobronchial ultrasound [EBUS])
• Ability to successfully navigate to lesion
• Use of associated tools and type (e.g., access tools, biopsy forceps,
cytology brush, aspiration needle)
• Number of lesions biopsied
• Number of lymph nodes biopsied (if applicable)
• Placement of fiducial markers (if applicable), type used, indication,
and status at follow-up imaging
• Surgical resection, including use of dye marker, type used, and
adequacy for surgical resection
• Diagnosis by both cytologic rapid on-site evaluation (ROSE) and pathology
• Cancer type (primary or metastatic), if applicable
• Cancer stage, if applicable
• Adequacy of sample for molecular testing and mutation type
(if applicable)
• Lymph node number, station, size, and success in obtaining sample
(if applicable)
• Number and type of repeat electromagnetic navigational
bronchoscopy (ENB) procedures or other biopsies
Table 2 Study assessments (Continued)
• Other health services (e.g., imaging, transfusion, surgery, emergency
room admission, prescriptions) received during admission for index
procedure
• Hospital admission duration
• Adverse events, action taken, relationship to device, and outcome
Follow-up assessments
• Subject satisfaction (at 1-month follow-up only)
• Subject quality of life (EQ-5D) at all follow-up visits
• ENB Productivity and Activity Questionnaire (ENB-PAQ) at 1 month
visit
• All health services (e.g., imaging, transfusion, surgery, emergency
room admission, prescriptions) received since last visit
• All healthcare services related to lung health since index procedure
(e.g., primary care and specialist visits, hospital, emergency room,
oncology, radiology, pain management).
• All therapeutic and diagnostic procedures and diagnoses related to
lung health since last visit
• Adverse events, action taken, relationship to device, and outcome
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Table 3 Study definitions
Bronchopulmonary hemorrhage
A disorder characterized by bleeding from the bronchial wall and/or lung parenchyma. Degree of severity will be classified according to Common
Terminology Criteria for Adverse Events (CTCAE) grade [38].The incidence of bronchopulmonary hemorrhage related to ENB index procedure rated
as Grade 2 or higher according to CTCAE scale will be captured and reported:
• Grade 2: Moderate symptoms; medical intervention indicated
• Grade 3: Transfusion, radiologic, endoscopic, or operative intervention indicated (e.g., hemostasis of bleeding site)
• Grade 4: Life-threatening respiratory or hemodynamic compromise; intubation or urgent intervention indicated
• Grade 5: Death
Bronchopulmonary hemorrhage will also be reported based on a newly validated airway bleeding scale (E. Folch and S. Khandhar, unpublished
personal communication; publication in progress).
Diagnostic yield
Diagnostic yield of the ENB procedure will be calculated on a per-subject basis out of all subjects in whom a diagnostic biopsy is attempted
and is defined as the proportion of subjects in whom the ENB procedure yielded a definitive diagnosis. Accuracy of all diagnoses aided by the
ENB procedure, as well as nondiagnostic cases, will evaluated based on 2-year clinical follow-up (see below).
Diagnostic accuracy
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) will be calculated as the accuracy of the ENB-aided diag-
nosis (based on final pathology results) compared to the final 2-year diagnosis based on all available procedures and follow-up.
Where a = true positive, b = false positive, c = false negative, and d = true negative:
• Sensitivity: Probability that an ENB-guided biopsy will be positive when malignancy is present (true positive rate): = a/(a + c)
• Specificity: Probability that an ENB-guided biopsy will be negative when malignancy is not present (true negative rate): = d/(b + d)
• PPV: Probability that malignancy is present when an ENB-guided biopsy is positive: = a/(a + b)
• NPV: Probability that malignancy is not present when an ENB-guided biopsy is negative: = d/(c + d)
Lesion size
Defined as greatest diameter of the target lesion.
Navigation Accuracy
Distance between the tip of the locatable guide and the targeted lung lesion (not done for lymph nodes).
Navigation success
The proportion of cases in which the operator is able to successfully navigate to the lung target with ENB guidance, based on investigator self-
assessment.
Navigation time
Total time that the locatable guide is used in the subject during the ENB procedure.
Peripheral lung lesion
A lesion that is located in the outer third of the lung and difficult to reach by traditional bronchoscopy (see Additional file 3, Peripheral Lung
Lesion Definition).
Pneumothorax
A disorder characterized by abnormal presence of air in the pleural cavity resulting in the collapse of the lung. The primary endpoint is the
incidence of pneumothorax related to the ENB index procedure rated as Grade 2 or higher. All grades will be captured as a secondary endpoint.
Degree of severity will be classified according to CTCAE grade as follows:
• Grade 1: Asymptomatic; clinical or diagnostic observations only; intervention not indicated.
• Grade 2: Symptomatic; intervention indicated (e.g., tube placement without sclerosis).
• Grade 3: Sclerosis and/or operative intervention indicated; hospitalization indicated.
• Grade 4: Life-threatening consequences; urgent intervention indicated.
• Grade 5: Death.
Pneumothorax severity will also be reported based on a newly validated scale that takes into account variance in international standard of care for
observation and intervention following asymptomatic pneumothorax and compared to the CTCAE criteria.
Procedure time
Time between initial introduction of the locatable guide into the body and final removal of the locatable guide.
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Roll-in subjects will be considered study participants
and will complete all protocol-required procedures and
follow-up. However, data for the roll-in group will be an-
alyzed separately from the remaining study population
in an effort to detect any differences in outcomes related
to the level of investigator experience.
Statistics
No sample size calculations were conducted for this
single-arm, observational study. All statistical analyses
will be performed using Statistical Analysis System
(SAS) for Windows (Version 9.2 or higher, SAS Institute
Inc. Cary, NC) or other widely accepted statistical or
graphical software.
Descriptive statistics will be used to present the
data and to summarize the results. Discrete variables
will be presented using frequency distributions and
cross tabulations. Continuous variables will be sum-
marized by presenting the number of observations
(n), mean, standard deviation, median, minimum, and
maximum values. For the primary endpoint, a 2-
sided 95 % exact binomial confidence interval will
also be provided.
In general, data analysis will be conducted on all
subjects who are enrolled in the trial and undergo an
ENB procedure. Analyses will be conducted on mul-
tiple subsets of study subjects based upon variables
such as geography, demographics, investigator experi-
ence, lesion and procedure characteristics, and other
variables as deemed appropriate. Multifactorial and
subgroup analyses evaluating the impact of patient
(e.g., medical and surgical history, risk profile), lesion
(e.g., size, location), and procedural characteristics
(e.g., rapid on-site evaluation use, tissue adequacy,
anesthesia method, use of complementary technology)
are planned.
Interim analyses are prespecified per protocol when
the first 500, 1000, and 1500 subjects enrolled reach the
1-month and 1-year follow-up timepoints.
Study organization
The sponsor will utilize a medical monitor to provide a
medical review and adjudication of pre-specified adverse
events in support of the protocol-defined endpoint data.
The medical monitor is a qualified, board-certified phys-
ician who is not affiliated with an investigative center or
the study sponsor.
In addition, a global Investigator Steering Committee
will provide oversight of study conduct, data analysis,
subject safety, and the publication of results in alignment
with recommendations of the International Committee of
Medical Journal Editors.
Enrollment status
Enrollment began in April 2015 and is currently in
progress. As of February 19, 2016, 500 subjects had
been enrolled at 23 clinical sites in the United States
and Europe. An interim analysis of the 1-month
follow-up of this first cohort is planned for the fall of
2016, with a focus on patient and lesion characteristics
and usage profile. Study enrollment is progressing on
schedule to reach the planned number of approxi-
mately 2,500 subjects; however, final enrollment num-
bers are not guaranteed.
Discussion
Current guidelines for the evaluation of patients suspected
of having lung cancer recommend the least invasive
method appropriate to the patient’s medical presentation,
with flexible bronchoscopy as the first line approach
for central lesions [42]. For peripheral lesions difficult
to reach with conventional bronchoscopy, options in-
clude percutaneous transthoracic CT- or fluoroscopy-
Table 3 Study definitions (Continued)
Repeat biopsy
Additional biopsy or biopsies conducted after the ENB-guided index procedure, required due to insufficient tissue collection for diagnosis at the
index procedure.
Respiratory failure
A disorder characterized by impaired gas exchange by the respiratory system resulting in hypoxemia and a decrease in oxygenation of the
tissues that may be associated with an increase in arterial levels of carbon dioxide. Degree of severity will be classified according to CTCAE
grade as follows:
• Grade 4: Life-threatening consequences; urgent intervention, intubation, or ventilatory support indicated.
• Grade 5: Death.
Stage
Lung cancer staging will be defined according to the Revised International System for Staging Lung Cancer (TNM) Classification System.
Tissue adequacy
Tissue adequacy is defined as the proportion of cases in which tissue obtained during the ENB index procedure is adequate for subtyping of lung
cancer and molecular testing when appropriate
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guided techniques or guided bronchoscopy. While
transthoracic needle aspiration (TTNA) is preferred
due to its high diagnostic yield, in a meta-analysis of
20 studies the mean pneumothorax rate was 25 %
(range 4.2 %–60 %) [43].
Guided bronchoscopic methods include ENB, radial
EBUS, and virtual bronchoscopy. A meta-analysis of
guided bronchoscopic methods found that the weighted
diagnostic yield of these techniques was higher than that
of traditional bronchoscopy but lower than the typical
yield of TTNA, with a wide variation among studies
[31]. Radial EBUS has a low pneumothorax rate (ap-
proximately 1 %), similar to that of ENB. Like ENB,
studies of radial EBUS-guided localization have reported
varied outcomes dependent on user experience, with
sensitivity for detection of malignancy ranging from
49 % to 88 % and a pooled sensitivity of 73 % [44]. Ra-
dial EBUS can be used in conjunction with ENB to con-
firm tumor location after initial navigation with ENB,
with higher diagnostic yield than either procedure alone
[9]. However, radial EBUS has been shown to have a
lower diagnostic yield in lesions ≤20 mm in size [44].
Virtual bronchoscopy using an ultrathin bronchoscope,
may also improve diagnostic yield when combined with
radial EBUS, but is not widely available and is limited by
the lack of a working channel for biopsy [45].
ENB procedures provide a minimally invasive, alterna-
tive method to access peripheral lung lesions and offer
the potential for biopsy, fiducial marker placement, and/
or dye marking in a single procedure. Access to smaller,
more peripheral lesions with a low risk of pneumothorax
may also allow diagnosis of lung cancer at an earlier
stage. However, current research is limited mostly to
small, single-center and single-operator studies, with
diagnostic yield estimates generally ranging between 59
and 94 %. In contrast, one recent registry reported a
diagnostic yield rate of only 38.5 % in 39 cases using
ENB guidance alone and 47.1 % in 266 cases using ENB
combined with EBUS, with overall diagnostic yield ran-
ging from 33 % to 73 % across the 10 included centers
[29]. Thus, the full picture of how ENB procedures are
used in clinical practice across diverse sites and geog-
raphies remains unclear. By providing a large, heteroge-
neous dataset, the NAVIGATE study will address several
important knowledge gaps and provide data on the real-
world use of ENB procedures.
Long-term data
Of the 24 published original studies on the use of ENB
procedures to aid in the diagnosis of peripheral lung le-
sions presented in Table 1, fewer than half reported on
patient outcomes beyond 1 year. Long-term data from
the NAVIGATE study will elucidate the accuracy of
ENB-aided diagnoses over time and provide valuable
information on how that diagnosis and the stage of diag-
nosis may influence the patient’s treatment path.
New data
The 3 published meta-analyses currently available on
ENB procedures all draw largely from the same dataset
[30–32]. NAVIGATE will provide an entirely unique
dataset derived from a diverse patient population. Fur-
thermore, because product versions and ancillary tools,
as well as the way operators use those tools, are con-
stantly evolving, NAVIGATE will provide an updated
source of information that the medical community can
use to evaluate this procedure to the present day. As
technology progresses and new products are introduced,
this will also be captured in NAVIGATE with the poten-
tial to examine the impact of technology iterations on
performance.
Generalizable data
With an enrollment cap of 75 subjects per site, NAVI-
GATE will collect data from a diverse array of sites, user
experience levels, and geographies. More importantly,
the study allows complete independence regarding user
preferences and diagnostic modalities. While all ancillary
biopsy tools, complementary imaging methods, and
follow-up procedures will be captured and reported,
NAVIGATE does not mandate the use of any specific
procedure. Rather, NAVIGATE is designed simply to
evaluate the clinical use of the ENB procedure in the
medical community. The eligibility criteria for enroll-
ment into NAVIGATE are intentionally broad to allow
an unrestricted assessment of how is ENB used in every-
day clinical practice in accordance with current guide-
lines. In particular, while ENB is typically thought of as a
tool for the evaluation of peripheral lesions, the profile
of ENB use for peripheral versus central lesions, primary
cancers versus metastatic disease, and operable versus
inoperable patients is not well known. NAVIGATE is de-
signed to capture that information and increase our un-
derstanding of the population of patients in whom ENB
is used and what patient profile is most appropriate for
the ENB procedure versus alternative methods. NAVI-
GATE will also evaluate the usage and utility of ENB-
aided samples for genetic testing, according to local
practice requirements. This will provide current infor-
mation to determine the value of ENB in this constantly
changing field of knowledge.
Standardized definitions
In addition to variations among user experience and pa-
tient characteristics, an important reason for the range
in ENB-aided diagnostic yield across studies is simply
the definition of diagnostic yield itself. Many studies lack
clearly defined performance outcomes or differ in how
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indeterminate results are handled. NAVIGATE will use
well-defined and widely accepted definitions of diagnos-
tic yield, sensitivity, specificity, and negative and positive
predictive value and evaluate the validity of those defini-
tions across a large dataset.
NAVIGATE will also evaluate the validity of common
definitions for pneumothorax and bronchopulmonary
hemorrhage. In particular, because there is no inter-
nationally standardized scale to measure airway bleeding,
NAVIGATE will pilot the use of a new scale developed
by investigators in this study and validated by expert
consensus (E. Folch and S. Khandhar, unpublished per-
sonal communication; publication in progress). This
scale will be evaluated side-by-side with the inter-
nationally standardized and recognized CTCAE grading
system [38]. Pneumothorax severity will also be evalu-
ated by a newly validated expert consensus scale that
takes into account variance in international standard of
care for observation and intervention following asymp-
tomatic pneumothorax and compared to the CTCAE
criteria (E. Folch and S. Khandhar, unpublished per-
sonal communication).
Stage migration
Only 15 % of all lung cancers are diagnosed at a local-
ized stage when the cancer is more amenable to surgical
resection for curative intent, which is typically associated
with the highest chance of long-term survival [2]. Diag-
nosis at an earlier stage also results in significant cost
savings [46]. With the ability to reach smaller, more per-
ipheral lesions, ENB procedures may theoretically enable
diagnosis of lung cancer at an earlier stage. A retrospect-
ive review of 286 cases of non–small-cell lung cancer in
a single center demonstrated that there was a greater
proportion of early-stage diagnoses after the introduc-
tion of ENB compared to before the introduction of
ENB [47]. NAVIGATE will prospectively assess stage at
diagnosis and other associated procedures within the
follow-up timeframe to confirm this result in a larger,
multicenter dataset.
Healthcare utilization and economic profile
One criticism of ENB is that it is more time-consuming
and expensive and requires more resources than other
techniques [30]. However, other studies have reported
that, despite higher acquisition cost, ENB procedures are
slightly less expensive than TTNA due to higher compli-
cation costs with TTNA [48]. NAVIGATE will assess
ENB costs, as well as downstream payments for follow-
up procedures, to determine how ENB – and potentially
an earlier diagnosis and lower pneumothorax rate – im-
pacts long-term cost-effectiveness. NAVIGATE will also
evaluate all healthcare services and procedures related to
lung cancer diagnosis and treatment following the initial
ENB index procedure through 2-year follow-up, for the
purpose of defining the treatment pathway after the ini-
tial ENB-aided diagnosis.
Predicting the probability of malignancy
With recent discussions on the value of screening for lung
cancer, the number of patients with positive CT findings is
likely to increase, particularly with the recommendations
for low-dose CT screening for high-risk individuals by
joint societies (e.g., Centers for Medicare and Medicaid
Services, Unites States Preventive Services Task Force, Na-
tional Comprehensive Cancer Network, American College
of Chest Physicians, Society of Thoracic Surgeons) [49].
Published studies have reported that approximately 25 %
of patients who undergo low-dose CT screening will have
a positive finding [3], with up to 50 % in smokers over the
age of 50 [50]. The anxiety and stress that patients experi-
ence from a positive CT finding can be further com-
pounded by the development of a complication during the
diagnostic workup. In the NLST study, 8.2 %–11.2 % of
patients diagnosed with lung cancer were associated with
having a major complication after an invasive procedure
[3]. Thus, there is an increasing need for appropriate tools
and information to guide physicians on how to handle
positive findings based on the clinical estimation of risk.
The clinician must evaluate the overall probability of ma-
lignancy in order to determine which patients can be
safely observed (<10 % probability of malignancy) and
which require immediate excision (>90 % probability of
malignancy). For moderately sized or indeterminate le-
sions, the appropriate course is often unclear. NAVIGATE
will provide information on which approach (watchful
waiting with serial CT scans, tissue biopsy, or direct exci-
sion) proves most effective over time based on pre-
procedure probability of malignancy and ENB findings.
NAVIGATE will also compare physician-estimated pre-
procedure probability of malignancy to a mathematical
model that calculates risk based on patient age, smoking
history, history of extrathoracic malignancy, nodule size,
nodule border characteristics, and nodule location [36,
37]. This calculation tool has been proven equivalent to
other estimation tools, requires few data points, is easy to
use, and is globally available. An ancillary objective of the
NAVIGATE study is to validate this tool in a larger dataset
and compare the long-term accuracy of the probability of
malignancy based on this calculation compared to the cli-
nician’s pre-procedure estimate.
Quality of life
Lung cancer patients are increasingly concerned with
quality of life and loss of lung function following surgical
resection. Physician and patient comfort levels and co-
morbidities must also be considered in every case. When
Folch et al. BMC Pulmonary Medicine  (2016) 16:60 Page 9 of 11
warranted, minimally invasive diagnostic options may be
preferred for patients with suspicious nodules and low
probability of malignancy.
NAVIGATE will assess patient health status and qual-
ity of life using the EQ-5D-3 L questionnaire [39, 40], a
standardized measure of health status over a 24-month
period. In addition, assessments of patient satisfaction,
healthcare utilization, and worker productivity will pro-
vide information on the impact of ENB on the con-
tinuum of care. Potential subgroup analyses might also
examine how quality of life, patient satisfaction, and
healthcare utilization differ based on the purpose of the
original ENB procedure (e.g., primary tumor versus
metastases, screening versus diagnosis, staging, marker
placement, etc.) and the diagnosis.
Conclusions
NAVIGATE will have a substantial impact on both the
pulmonology and thoracic surgery communities. With
up to 2,500 subjects planned, NAVIGATE will be ap-
proximately 10 times larger than the largest ENB study
to date. The intent of the study is to investigate real-
world utilization patterns and outcomes in a broad range
of both academic and community centers, including
evaluations of diagnostic yield and accuracy and of suc-
cess rates of fiducial marker placement, dye marking,
and lymph node biopsies. Additionally, subgroup ana-
lyses are planned based on geography, patient demo-
graphics and medical history, investigator experience,
and lesion and procedure characteristics. This study will
answer questions that remain largely unexplored in a
large multi-center trial and will provide a wealth of in-
formation to the medical community regarding the full
profile of ENB usage. In addition, clinical utility and out-
comes identified in NAVIGATE will be instructive for
the design of future comparative studies.
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